TriangleLN-145 (NCT04614103)
LN-145 trial for Metastatic Non Small Cell Lung Cancer (NCT04614103). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic non-small-cell lung cancer after progression on checkpoint immunotherapy and platinum chemotherapy. EGFR, ALK, and ROS1 alterations exclude participation. Most participants must be seventy or younger; exceptions require discussion.
The idea: LN-145 expands immune cells from a patient's tumor to attack that cancer. Tumor surgery or cohort-specific biopsy provides cells. Cyclophosphamide and fludarabine precede the cell infusion; interleukin-two follows. Researchers measure tumor response and safety.
This phase 2 study plans 170 patients. Iovance sponsors the study; twenty-one US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.